Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

A high CD34+ cell dose is associated with better disease-free survival in patients with low-risk diseases undergoing peripheral blood stem cell transplantation from HLA-matched related donors.

Yokoyama Y, Maie K, Fukuda T, Uchida N, Mukae J, Sawa M, Kubo K, Kurokawa M, Nakamae H, Ichinohe T, Atsuta Y, Chiba S.

Bone Marrow Transplant. 2020 Feb 10. doi: 10.1038/s41409-020-0817-5. [Epub ahead of print]

PMID:
32042104
2.

[Pulmonary infiltration of acute monoblastic leukemia diagnosed by transbronchial lung biopsy].

Harada N, Nakane T, Okamura H, Nanno S, Nakashima Y, Koh H, Tanaka S, Ohsawa M, Hino M, Nakamae H.

Rinsho Ketsueki. 2020;61(1):27-32. doi: 10.11406/rinketsu.61.27. Japanese.

PMID:
32023598
3.

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.

Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, Tanaka H, Shindo M, Kumagai T, Ikezoe T, Uoshima N, Sato T, Watanabe R, Kowata S, Hayakawa M, Hosoki T, Ikeda K, Kobayashi T, Kakinoki Y, Nishimoto T, Takezako N, Shibayama H, Takaori-Kondo A, Nakamae H, Kawaguchi A, Ureshino H, Sakamoto J, Ishida Y; DADI Trial Group.

Lancet Haematol. 2020 Jan 21. pii: S2352-3026(19)30235-2. doi: 10.1016/S2352-3026(19)30235-2. [Epub ahead of print]

PMID:
31978329
4.

Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by Stenotrophomonas maltophilia.

Imoto W, Yamada K, Yamairi K, Shibata W, Namikawa H, Yukawa S, Yoshii N, Nakaie K, Hirose A, Koh H, Watanabe T, Asai K, Nakamae H, Kaneko Y, Kawaguchi T, Hino M, Kakeya H.

Intern Med. 2020;59(2):193-198. doi: 10.2169/internalmedicine.3358-19. Epub 2020 Jan 15.

5.

Donor KIR2DS1-Mediated Decreased Relapse and Improved Survival Depending on Remission Status at HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.

Ido K, Koh H, Hirose A, Okamura H, Koh S, Nanno S, Nishimoto M, Nakamae M, Nakashima Y, Nakane T, Hino M, Nakamae H.

Biol Blood Marrow Transplant. 2019 Dec 31. pii: S1083-8791(19)31733-1. doi: 10.1016/j.bbmt.2019.12.765. [Epub ahead of print]

PMID:
31899360
6.

Pretransplant serum beta-2 microglobulin level is a potential novel prognostic marker of overall survival after allogeneic hematopoietic cell transplantation - a retrospective observational study.

Harada N, Nakane T, Nakamae M, Hashimoto Y, Okamura H, Nanno S, Nishimoto M, Hirose A, Nakashima Y, Koh H, Hino M, Nakamae H.

Transpl Int. 2019 Dec 13. doi: 10.1111/tri.13564. [Epub ahead of print]

PMID:
31834655
7.

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for ATL with HTLV-1 Antibody-Positive Donors.

Yoshimitsu M, Fuji S, Utsunomiya A, Nakano N, Ito A, Ito Y, Miyamoto T, Suehiro Y, Kawakita T, Moriuchi Y, Nakamae H, Kanda Y, Ichinohe T, Fukuda T, Atsuta Y, Kato K; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant. 2019 Dec 9. pii: S1083-8791(19)30839-0. doi: 10.1016/j.bbmt.2019.12.004. [Epub ahead of print]

PMID:
31821886
8.

Mosquito allergy: a novel strong prognostic symptom of outcome after allogeneic hematopoietic transplantation.

Koh S, Nakamae H, Nanno S, Nakane T, Nakashima Y, Koh H, Nakamae M, Hirose A, Hino M.

Bone Marrow Transplant. 2019 Dec 5. doi: 10.1038/s41409-019-0759-y. [Epub ahead of print] No abstract available.

PMID:
31804620
9.

Combination of Frailty Status and Comorbidity Score Improves the Stratification of Survival in Patients With Myelodysplastic Syndrome Owing to Good Predictive Capability for Infection-related Mortality.

Sakatoku K, Takeoka Y, Miura A, Araki T, Fujitani Y, Yamamura R, Nakamae H, Ohta K, Hino M.

Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):799-805. doi: 10.1016/j.clml.2019.09.610. Epub 2019 Sep 28.

PMID:
31648956
10.

Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Yanada M, Konuma T, Yamasaki S, Kuwatsuka Y, Masuko M, Tanaka M, Ozawa Y, Toya T, Fukuda T, Ota S, Sawa M, Uchida N, Nakamae H, Eto T, Kanda J, Takanashi M, Kanda Y, Atsuta Y, Yano S.

Biol Blood Marrow Transplant. 2020 Feb;26(2):307-315. doi: 10.1016/j.bbmt.2019.09.036. Epub 2019 Oct 9.

PMID:
31605818
11.

Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation.

Fuji S, Oshima K, Ohashi K, Sawa M, Saito T, Eto T, Tanaka M, Onizuka M, Nakamae H, Shiratori S, Ozawa Y, Hidaka M, Nagamura-Inoue T, Tanaka H, Fukuda T, Ichinohe T, Atsuta Y, Ogata M.

Bone Marrow Transplant. 2019 Oct 7. doi: 10.1038/s41409-019-0712-0. [Epub ahead of print]

PMID:
31591450
12.

Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients.

Nakane T, Okamura H, Tagaito Y, Koh S, Yoshimura T, Makuuchi Y, Nanno S, Nakamae M, Hirose A, Nakashima Y, Koh H, Hino M, Nakamae H.

Int J Hematol. 2019 Dec;110(6):736-742. doi: 10.1007/s12185-019-02743-6. Epub 2019 Sep 27.

PMID:
31560116
13.

Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).

Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y.

Int J Hematol. 2019 Dec;110(6):675-682. doi: 10.1007/s12185-019-02736-5. Epub 2019 Sep 19.

PMID:
31538327
14.

Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications: A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group.

Shinohara A, Oshima K, Fuji S, Umeda K, Kako S, Kurokawa M, Tsukada N, Kasai M, Kondo T, Hashii Y, Nakamae H, Ikegame K, Kosaka Y, Shimada A, Nawa Y, Makoto Y, Yoshiko A, Fukuda T, Tanaka J, Ogata M.

Biol Blood Marrow Transplant. 2020 Jan;26(1):66-75. doi: 10.1016/j.bbmt.2019.08.021. Epub 2019 Sep 5.

PMID:
31494230
15.

A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors.

Nakamae H, Fujii K, Nanno S, Okamura H, Nakane T, Koh H, Nakashima Y, Nakamae M, Hirose A, Teshima T, Hino M.

Transpl Int. 2019 Dec;32(12):1322-1332. doi: 10.1111/tri.13494. Epub 2019 Sep 9.

PMID:
31432532
16.

Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph + ALL with minimal residual disease.

Nishiwaki S, Mizuta S, Ohashi K, Fukuda T, Uchida N, Tachibana T, Onizuka M, Ozawa Y, Onishi Y, Takahashi S, Eto T, Nakamae H, Tanaka J, Ichinohe T, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Am J Hematol. 2019 Nov;94(11):E301-E305. doi: 10.1002/ajh.25612. Epub 2019 Aug 26. No abstract available.

PMID:
31403213
17.

Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Akahoshi Y, Nishiwaki S, Mizuta S, Ohashi K, Uchida N, Tanaka M, Fukuda T, Ozawa Y, Takahashi S, Onizuka M, Shiratori S, Nakamae H, Kanda Y, Ichinohe T, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Cancer Sci. 2019 Oct;110(10):3255-3266. doi: 10.1111/cas.14167. Epub 2019 Aug 29.

18.

Clinical Impacts of Using Serum IL-6 Level as an Indicator of Cytokine Release Syndrome after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.

Nishimoto M, Hirose A, Koh H, Nakamae M, Nanno S, Okamura H, Nakane T, Nakashima Y, Hino M, Nakamae H.

Biol Blood Marrow Transplant. 2019 Oct;25(10):2061-2069. doi: 10.1016/j.bbmt.2019.06.003. Epub 2019 Jun 10.

PMID:
31195139
19.

BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient.

Nakasone H, Kawamura K, Yakushijin K, Shinohara A, Tanaka M, Ohashi K, Ota S, Uchida N, Fukuda T, Nakamae H, Matsuoka KI, Kanda J, Ichinohe T, Atsuta Y, Inamoto Y, Seo S, Kimura F, Ogata M.

Blood Adv. 2019 Jun 11;3(11):1750-1760. doi: 10.1182/bloodadvances.2019000077.

20.

Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission.

Yano S, Yokoyama H, Yanada M, Mori J, Aoki J, Ohashi K, Kanomori H, Ozawa Y, Sawa M, Nakamae H, Eto T, Ohta S, Tanaka J, Ichinohe T, Atsuta Y, Takami A.

Bone Marrow Transplant. 2019 Dec;54(12):2004-2012. doi: 10.1038/s41409-019-0571-8. Epub 2019 May 31.

PMID:
31152148
21.

A noninvasive diagnostic approach using per-rectal portal scintigraphy for sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation.

Okamura H, Koh H, Takakuwa T, Ido K, Makuuchi Y, Ine S, Nanno S, Nakashima Y, Nakane T, Jogo A, Yamamoto A, Hamuro M, Kotani K, Kawabe J, Higashiyama S, Yoshida A, Shiomi S, Ohsawa M, Hino M, Nakamae H.

Bone Marrow Transplant. 2020 Feb;55(2):470-472. doi: 10.1038/s41409-019-0537-x. Epub 2019 May 14. No abstract available.

PMID:
31089276
22.

Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience.

Yanada M, Konuma T, Kuwatsuka Y, Kondo T, Kawata T, Takahashi S, Uchida N, Miyakoshi S, Tanaka M, Ozawa Y, Sawa M, Nakamae H, Aotsuka N, Kanda J, Takanashi M, Kanda Y, Atsuta Y, Yano S.

Bone Marrow Transplant. 2019 Nov;54(11):1789-1798. doi: 10.1038/s41409-019-0539-8. Epub 2019 May 8.

PMID:
31068659
23.

Short-Term Fasting Induces Cell Cycle Arrest in Immature Hematopoietic Cells and Increases the Number of Naïve T Cells in the Bone Marrow of Mice.

Takakuwa T, Nakashima Y, Koh H, Nakane T, Nakamae H, Hino M.

Acta Haematol. 2019;141(3):189-198. doi: 10.1159/000496096. Epub 2019 Mar 6.

PMID:
30840964
24.

The Proportional Relationship Between Pretransplant WT1 mRNA Levels and Risk of Mortality After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission.

Ido K, Nakamae M, Koh H, Okamura H, Nanno S, Nishimoto M, Takeoka Y, Hirose A, Nakashima Y, Hashimoto Y, Nakane T, Hino M, Nakamae H.

Transplantation. 2019 Oct;103(10):2201-2210. doi: 10.1097/TP.0000000000002662.

PMID:
30801534
25.

Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma.

Sawayama Y, Itonaga H, Fukushima T, Nakano N, Fujiwara H, Utsunomiya A, Fukuda T, Miyamoto T, Eto T, Miyashita K, Nakamae H, Ogata M, Yamanoha A, Miyazaki Y, Kanda J, Atsuta Y, Kato K; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Am J Hematol. 2019 May;94(5):E143-E146. doi: 10.1002/ajh.25438. Epub 2019 Mar 6. No abstract available.

PMID:
30773707
26.

[Refractory ascites caused by lymphatic flow disorder after stem cell transplantation for acute myeloid leukemia].

Takakuwa T, Okuno T, Nishimoto M, Nanno S, Takeoka Y, Nakashima Y, Koh H, Nakane T, Wanibuchi H, Hino M, Nakamae H.

Rinsho Ketsueki. 2019;60(1):12-16. doi: 10.11406/rinketsu.60.12. Japanese.

PMID:
30726817
27.

Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation.

Fujiwara SI, Kanda J, Tatara R, Ogawa H, Fukuda T, Okumura H, Ohashi K, Iwato K, Ueda Y, Ishiyama K, Eto T, Matsuoka KI, Nakamae H, Onizuka M, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Bone Marrow Transplant. 2019 Aug;54(8):1327-1336. doi: 10.1038/s41409-019-0434-3. Epub 2019 Jan 22.

PMID:
30670824
28.

[Successful treatment with rituximab in acute disseminated encephalomyelitis with whole spinal cord involvement following HLA haploidentical transplantation].

Makuuchi Y, Nishimoto M, Yamamoto K, Takahashi T, Kuno M, Nakashima Y, Koh H, Nakane T, Hino M, Nakamae H.

Rinsho Ketsueki. 2018;59(12):2588-2593. doi: 10.11406/rinketsu.59.2588. Japanese.

PMID:
30626794
29.

Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.

Wakamatsu M, Terakura S, Ohashi K, Fukuda T, Ozawa Y, Kanamori H, Sawa M, Uchida N, Ota S, Matsushita A, Kanda Y, Nakamae H, Ichinohe T, Kato K, Murata M, Atsuta Y, Teshima T; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Blood Adv. 2019 Jan 22;3(2):105-115. doi: 10.1182/bloodadvances.2018025643.

30.

HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome.

Maeda Y, Ugai T, Kondo E, Ikegame K, Murata M, Uchida N, Miyamoto T, Takahashi S, Ohashi K, Nakamae H, Fukuda T, Onizuka M, Eto T, Ota S, Hirokawa M, Ichinohe T, Atsuta Y, Kanda Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Haematologica. 2019 May;104(5):1055-1061. doi: 10.3324/haematol.2018.204438. Epub 2018 Dec 6.

31.

Successful treatment of invasive pulmonary aspergillosis caused by Aspergillus felis, a cryptic species within the Aspergillus section Fumigati: A case report.

Yamairi K, Ido K, Nakamura S, Niki M, Imoto W, Shibata W, Namikawa H, Fujimoto H, Yamada K, Nakamae H, Hino M, Kaneko Y, Miyazaki Y, Kakeya H.

J Infect Chemother. 2019 Apr;25(4):307-310. doi: 10.1016/j.jiac.2018.10.016. Epub 2018 Nov 30.

PMID:
30503017
32.

Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma.

Yamasaki S, Chihara D, Kim SW, Kawata T, Mizuta S, Ago H, Chou T, Yamane T, Uchiyama H, Oyake T, Miura K, Saito B, Taji H, Nakamae H, Miyamoto T, Fukuda T, Kanda J, Atsuta Y, Suzuki R.

Int J Hematol. 2019 Feb;109(2):175-186. doi: 10.1007/s12185-018-2560-x. Epub 2018 Nov 14.

PMID:
30430419
33.

Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis.

Konuma T, Harada K, Yamasaki S, Mizuno S, Uchida N, Takahashi S, Onizuka M, Nakamae H, Hidaka M, Fukuda T, Ohashi K, Kohno A, Matsushita A, Kanamori H, Ashida T, Kanda J, Atsuta Y, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Am J Hematol. 2019 Jan;94(1):103-110. doi: 10.1002/ajh.25336. Epub 2018 Nov 29.

34.

Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.

Konuma T, Shimomura Y, Ozawa Y, Ueda Y, Uchida N, Onizuka M, Akiyama M, Mori T, Nakamae H, Ohno Y, Shiratori S, Onishi Y, Kanda Y, Fukuda T, Atsuta Y, Ishiyama K; Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Hematol Oncol. 2019 Feb;37(1):85-95. doi: 10.1002/hon.2566. Epub 2018 Nov 19.

PMID:
30370627
35.

The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation.

Kato K, Uike N, Wake A, Yoshimitsu M, Tobai T, Sawayama Y, Takatsuka Y, Fukuda T, Uchida N, Eto T, Nakashima Y, Kondo T, Taguchi J, Miyamoto T, Nakamae H, Ichinohe T, Kato K, Suzuki R, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Hematol Oncol. 2019 Feb;37(1):54-61. doi: 10.1002/hon.2558. Epub 2018 Sep 28.

PMID:
30171618
36.

Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades.

Yanada M, Masuko M, Mori J, Aoki J, Mizuno S, Fukuda T, Kakihana K, Ozawa Y, Ota S, Kanamori H, Mori T, Nakamae H, Eto T, Shiratori S, Maeda T, Iwato K, Ichinohe T, Kanda Y, Tanaka J, Atsuta Y, Yano S.

Bone Marrow Transplant. 2019 Apr;54(4):578-586. doi: 10.1038/s41409-018-0301-7. Epub 2018 Aug 14.

PMID:
30108330
37.

Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation.

Inamoto Y, Matsuda T, Tabuchi K, Kurosawa S, Nakasone H, Nishimori H, Yamasaki S, Doki N, Iwato K, Mori T, Takahashi S, Yabe H, Kohno A, Nakamae H, Sakura T, Hashimoto H, Sugita J, Ago H, Fukuda T, Ichinohe T, Atsuta Y, Yamashita T; Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group.

Blood Adv. 2018 Aug 14;2(15):1901-1913. doi: 10.1182/bloodadvances.2018020966.

38.

Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).

Konuma T, Mizuno S, Kondo T, Yamaguchi H, Fukuda T, Uchida N, Najima Y, Kanamori H, Ota S, Nakamae H, Nakamae M, Mizuno I, Sugita J, Onishi Y, Yokota A, Takahashi S, Kanda Y, Ichinohe T, Atsuta Y, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Ann Hematol. 2018 Nov;97(11):2173-2183. doi: 10.1007/s00277-018-3419-1. Epub 2018 Jul 6.

PMID:
29978286
39.

Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia.

Hashimoto Y, Nakamae H, Tanaka T, Omura H, Horiuchi M, Yoshimura T, Takakuwa T, Mugitani A, Hirose A, Nakamae M, Koh H, Hino M.

Eur J Haematol. 2018 Oct;101(4):508-513. doi: 10.1111/ejh.13136. Epub 2018 Aug 31.

PMID:
29971894
40.

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.

Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Mizuta S, Hashino S, Nomura T, Shikami M, Fukutani H, Ohe Y, Kosugi H, Shibayama H, Maeda Y, Fukushima T, Yamazaki H, Tsubaki K, Kukita T, Adachi Y, Nataduka T, Sakoda H, Yokoyama H, Okamoto T, Shirasugi Y, Onishi Y, Nohgawa M, Yoshihara S, Morita S, Sakamoto J, Kimura S; DADI Trial Group, Japan.

Clin Lymphoma Myeloma Leuk. 2018 May;18(5):353-360.e1. doi: 10.1016/j.clml.2018.03.004. Epub 2018 Mar 15.

41.

Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).

Ishikawa J, Matsumura I, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Matsuoka KI, Shibayama H, Hino M, Hirase C, Kamimura T, Shimose T, Akashi K, Kanakura Y.

Int J Hematol. 2018 May;107(5):535-540. doi: 10.1007/s12185-018-2401-y. Epub 2018 Jan 23.

PMID:
29362980
42.

The First Case of Non-leukemic Sarcoma Composed of Mixed-phenotype Acute Leukemia, B/myeloid, Not Otherwise Specified.

Takakuwa T, Nakane T, Ohsawa M, Nagasaki J, Aoyama Y, Nishimoto M, Hayashi Y, Kuwae Y, Hino M, Nakamae H.

Intern Med. 2018 Apr 15;57(8):1155-1158. doi: 10.2169/internalmedicine.9144-17. Epub 2017 Dec 21.

43.

Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia.

Arima N, Kanda J, Tanaka J, Yabe T, Morishima Y, Kim SW, Najima Y, Ozawa Y, Eto T, Kanamori H, Mori T, Kobayashi N, Kondo T, Nakamae H, Uchida N, Inoue M, Fukuda T, Ichinohe T, Atsuta Y, Kanda Y.

Biol Blood Marrow Transplant. 2018 Apr;24(4):717-725. doi: 10.1016/j.bbmt.2017.11.029. Epub 2017 Dec 27.

44.

Impact of a Low CD34+ Cell Dose on Allogeneic Peripheral Blood Stem Cell Transplantation.

Yamamoto C, Ogawa H, Fukuda T, Igarashi A, Okumura H, Uchida N, Hidaka M, Nakamae H, Matsuoka KI, Eto T, Ichinohe T, Atsuta Y, Kanda Y.

Biol Blood Marrow Transplant. 2018 Apr;24(4):708-716. doi: 10.1016/j.bbmt.2017.10.043. Epub 2017 Nov 28.

45.

Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.

Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H.

Int J Hematol. 2018 Mar;107(3):327-336. doi: 10.1007/s12185-017-2353-7. Epub 2017 Oct 26.

PMID:
29076005
46.

Picosecond tunable gain-switched blue pulses from GaN laser diodes with nanosecond current injections.

Chen S, Nakamura T, Ito T, Bao X, Nakamae H, Weng G, Hu X, Yoshita M, Akiyama H, Liu J, Ikeda M, Yang H.

Opt Express. 2017 Jun 12;25(12):13046-13054. doi: 10.1364/OE.25.013046.

PMID:
28788844
47.

An Elderly Woman with Anti-neutrophil Antibody-positive Agranulocytosis Who Responded to High-dose Intravenous Methylprednisolone.

Koh S, Koh H, Kubo Y, Kuroda M, Nishimoto M, Yoshimura T, Nakashima Y, Nakane T, Nakamae H, Ohsawa M, Hino M.

Intern Med. 2017 Aug 15;56(16):2199-2203. doi: 10.2169/internalmedicine.8268-16. Epub 2017 Aug 1.

48.

Diagnostic value of serum ferritin and cytokine profiles of hemophagocytic syndrome following allogeneic hematopoietic cell transplantation: methodological issues.

Koh H, Nanno S, Hino M, Nakamae H.

Leuk Lymphoma. 2018 Mar;59(3):772-773. doi: 10.1080/10428194.2017.1361033. Epub 2017 Aug 4. No abstract available.

PMID:
28776428
49.

Clinicopathologic significance of the CXCL1-CXCR2 axis in the tumor microenvironment of gastric carcinoma.

Kasashima H, Yashiro M, Nakamae H, Masuda G, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Nakane T, Hino M, Hirakawa K, Ohira M.

PLoS One. 2017 Jun 2;12(6):e0178635. doi: 10.1371/journal.pone.0178635. eCollection 2017.

50.

Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.

Kondo T, Nagamura-Inoue T, Tojo A, Nagamura F, Uchida N, Nakamae H, Fukuda T, Mori T, Yano S, Kurokawa M, Ueno H, Kanamori H, Hashimoto H, Onizuka M, Takanashi M, Ichinohe T, Atsuta Y, Ohashi K.

Am J Hematol. 2017 Sep;92(9):902-908. doi: 10.1002/ajh.24793. Epub 2017 Jun 9.

Supplemental Content

Loading ...
Support Center